Efficacy of inhaled medications in asthma and COPD related to disease severity

References

• Rau JL. The inhalation of drugs: advantages and problems. Respir Care. 2005;50:367–382.
   PubMedGoogle Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:600–612. doi:10.1046/j.1365-2125.2003.01893.x.
   PubMed Web of Science ®Google Scholar
• Louridas G, Kakoura M, Galanis N, et al. Bronchodilatory effect of inhaled versus oral salbutamol in bronchial asthma. Respiration. 1983;44:439–443. doi:10.1159/000194582.
   PubMed Web of Science ®Google Scholar
• Grimwood K, Johnson-Barrett JJ, Taylor B. Salbutamol: tablets, inhalational powder, or nebuliser? Br Med J (Clin Res Ed). 1981;282:105–106. doi:10.1136/bmj.282.6258.105.
   PubMed Web of Science ®Google Scholar
• Dulfano MJ, Glass P. The bronchodilator effects of terbutaline: route of administration and patterns of response. Ann Allergy. 1976;37:357–366.
   PubMedGoogle Scholar
• Thiringer G, Svedmyr N. Comparison of infused and inhaled terbutaline in patients with asthma. Scand J Respir Dis. 1976;57:17–24.
   PubMedGoogle Scholar
• Matthys H. Inhalation delivery of asthma drugs. Lung. 1990;168(Suppl):645–652. doi:10.1007/BF02718189.
   PubMed Web of Science ®Google Scholar
• Pedersen S. Inhalers and nebulizers: which to choose and why. Respir Med. 1996;90:69–77. doi:10.1016/S0954-6111(96)90201-2.
   PubMed Web of Science ®Google Scholar
• Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50:1313–21; Discussion 1321–2.
   Google Scholar
• Borgström L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med Off J Int Soc Aerosols Med. 2001;14:281–287. doi:10.1089/089426801316970231.
   PubMedGoogle Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–371. doi:10.1378/chest.127.1.335.
   PubMed Web of Science ®Google Scholar
• Fromer L, Goodwin E, Walsh J. Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med. 2010;122:83–93. doi:10.3810/pgm.2010.03.2125.
   PubMed Web of Science ®Google Scholar
• Stevens N. Inhaler devices for asthma and COPD: choice and technique. Prof Nurse. 2003;18:641–645.
   PubMedGoogle Scholar
• Hanania NA, Wittman R, Kesten S, et al. Medical personnel’s knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest. 1994;105:111–116. doi:10.1378/chest.105.1.111.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938. doi:10.1016/j.rmed.2011.01.005.
   PubMed Web of Science ®Google Scholar
• Chorão P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD – an assessment of inhaler technique and patient preferences. Respir Med. 2014;108:968–975. doi:10.1016/j.rmed.2014.04.019.
   PubMed Web of Science ®Google Scholar
• Takemura M, Kobayashi M, Kimura K, et al. Repeated instruction on inhalation technique improves adherence to the therapeutic regimen in asthma. J Asthma Off J Assoc Care Asthma. 2010;47:202–208. doi:10.3109/02770900903581692.
   PubMed Web of Science ®Google Scholar
• Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50:1360–1374 [Discussion:1374–65].
   Google Scholar
• Gold PM. The 2007 GOLD guidelines: a comprehensive care framework. Respir Care. 2009;54:1040–1049.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–178. doi:10.1183/09031936.00138707.
   PubMed Web of Science ®Google Scholar
• Molimard M. How to achieve good compliance and adherence with inhalation therapy. Curr Med Res Opin. 2005;21(Suppl 4):S33–37. doi:10.1185/030079905X61776.
   Google Scholar
• Mitchell JP. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2012;39:1054–1055;author reply 1055–6. doi:10.1183/09031936.00210911.
   Web of Science ®Google Scholar
• Vinchurkar S, Backer LD, Vos W, et al. A case series on lung deposition analysis of inhaled medication using functional imaging based computational fluid dynamics in asthmatic patients: effect of upper airway morphology and comparison with in vivo data. Inhal Toxicol. 2012;24:81–88. doi:10.3109/08958378.2011.644351.
   PubMed Web of Science ®Google Scholar
• De Backer JW, Vos WG, Gorlé CD, et al. Flow analyses in the lower airways: patient-specific model and boundary conditions. Med Eng Phys. 2008;30:872–879.
   PubMed Web of Science ®Google Scholar
• De Backer J, Vos W, Vinchurkar S, et al. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J Aerosol Med Pulm Drug Deliv. 2015;28:88–99. doi:10.1089/jamp.2013.1064.
   PubMed Web of Science ®Google Scholar
• Vos W, De Backer J, Poli G, et al. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone/formoterol. Respiration. 2013;86:393–401.
   PubMed Web of Science ®Google Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137–148. doi:10.1089/jamp.2009.0772.
   PubMed Web of Science ®Google Scholar
• Kanniess F, Scuri M, Vezzoli S, et al. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: a randomised, double-blind trial. Pulm Pharmacol Ther. 2015;30:121–127. doi:10.1016/j.pupt.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Gallegos CM, Silveira LJ, et al. Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. Allergy Asthma Proc Off J Reg State Allergy Soc. 2009;30:284–292. doi:10.2500/aap.2009.30.3235.
   PubMed Web of Science ®Google Scholar
• Tunon-de-Lara JM, Laurent F, Giraud V, et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol. 2007;119:583–590. doi:10.1016/j.jaci.2006.11.005.
   PubMed Web of Science ®Google Scholar
• De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257:854–862.
   PubMed Web of Science ®Google Scholar
• Scichilone N, Spatafora M, Battaglia S, et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy. 2013;6:11–21.
   Google Scholar
• Vos W, Hajian B, De Backer J, et al. Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA. Int J Chronic Obstructive Pulm Dis. 2016;11:263–271. doi:10.2147/COPD.S93830.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–866.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154–161. doi:10.1164/rccm.200610-1563OC.
   PubMed Web of Science ®Google Scholar
• De Backer J, Vos W, Van Holsbeke C, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J Chron Obstruct Pulmon Dis. 2013;8:569–579. doi:10.2147/COPD.S49307.
   PubMed Web of Science ®Google Scholar
• De Backer L, Vos W, Dieriks B, et al. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. Int J Chron Obstruct Pulmon Dis. 2011;6:615–624. doi:10.2147/COPD.S22823.
   PubMed Web of Science ®Google Scholar
• Agustí A, Rennard S, Edwards LD, et al. Clinical and prognostic heterogeneity of C and D GOLD groups. Eur Respir J. 2015;46:250–254. doi:10.1183/09031936.00012215.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Locantore N, Delafont B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12:303–312. doi:10.1513/AnnalsATS.201403-125OC.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Agusti A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med. 2014;189:1022–1030. doi:10.1164/rccm.201311-2006PP.
   PubMed Web of Science ®Google Scholar
• Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42:636–646. doi:10.1183/09031936.00195212.
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122. doi:10.1186/1465-9921-11-122.
   PubMed Web of Science ®Google Scholar
• De Backer W, Vos W, Van Holsbeke C, et al. The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients. Eur Respir J. 2014;44:527–529. doi:10.1183/09031936.00011714.
   PubMed Web of Science ®Google Scholar